Literature DB >> 8541291

NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) at an external site.

D J Morré1.   

Abstract

NADH oxidase activity from HeLa plasma membranes was inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984). With sealed right side-out vesicles, the drug inhibited half maximally at about 30 nM and the inhibition was nearly complete. A closely related but growth-inactive sulfonylurea, N-(4-methylphenylsulfonyl)-N'-(phenyl)urea (LY181985), did not inhibit the activity. With plasma membranes first solubilized with 2% Triton X-100, activity also was inhibited by LY181984 and not by LY181985 but the maximum inhibition at 10 microM LY181984 was only 50%. When sealed right side-out plasma membrane vesicles were frozen and thawed repeatedly to evert some of the vesicles into an inside-out configuration, the NADH oxidase activity again was only about 50% inhibited by 1 microM LY181984. In such preparations, the right side-out vesicles exhibited an electrophoretic mobility greater than that of the inside-out vesicles. Sidedness was confiremd by measurements of ATPase latency and binding of immunogold-labeled concanavalin A. When the two vesicle populations were resolved by preparative free-flow electrophoresis, the active antitumor sulfonylurea LY181984 inhibited only the NADH oxidase activity of the right side-out vesicles. These findings suggested two NADH sites or activity isoforms for the plasma membrane NADH oxidase. One activity, inhibited by LY181984, appeared to be accessible to external NADH only with sealed right side-out vesicles. The other, not inhibited by LY181984, was accessible to NADH only with inside-out vesicles or after membrane disruption by Triton X-100. The findings demonstrate that the NADH oxidation site inhibited as a result of binding the active antitumor sulfonylurea LY181984 is at the external cell surface. Plasma membrane vesicles from HeLa cells are able to oxidize NADH supplied to either membrane surface but only with inside-out vesicles is NADH oxidation sensitive to inhibition by the antitumor sulfonylurea.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541291     DOI: 10.1016/0005-2736(95)00199-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Essential role of copper in the activity and regular periodicity of a recombinant, tumor-associated, cell surface, growth-related and time-keeping hydroquinone (NADH) oxidase with protein disulfide-thiol interchange activity (ENOX2).

Authors:  Xiaoyu Tang; P-J Chueh; Ziying Jiang; Sara Layman; Berdine Martin; Chinpal Kim; Dorothy M Morré; D James Morré
Journal:  J Bioenerg Biomembr       Date:  2010-10-05       Impact factor: 2.945

2.  Structural changes revealed by Fourier transform infrared and circular dichroism spectroscopic analyses underlie tNOX periodic oscillations.

Authors:  Chinpal Kim; Sara Layman; Dorothy M Morré; D James Morré
Journal:  Dose Response       Date:  2006-05-01       Impact factor: 2.658

3.  The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity.

Authors:  D J Morré; P J Chueh; J Lawler; D M Morré
Journal:  J Bioenerg Biomembr       Date:  1998-10       Impact factor: 2.945

4.  A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.

Authors:  D J Morré; T Reust
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

5.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

6.  Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin.

Authors:  D James Morré; Nicole McClain; L-Y Wu; Graham Kelly; Dorothy M Morré
Journal:  Mol Biotechnol       Date:  2009-01-21       Impact factor: 2.695

7.  ENOX2 target for the anticancer isoflavone ME-143.

Authors:  D James Morré; Theodore Korty; Christiaan Meadows; Laura M C Ades; Dorothy M Morré
Journal:  Oncol Res       Date:  2014       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.